ATR-01 — IND submission
2026
We are planning to perform lead optimization and IND-enabling studies in 2025 to support an IND filing in 2026.Source filing
AZTR biotech catalysts & pipeline
AZITRA INC · Data as of 2026-09-08
Upcoming catalysts
ATR-04 — Topline data
Q3 2026
In August 2024, we obtained IND clearance from the FDA to commence a Phase 1/2 clinical trial in certain cancer patients undergoing EGFRi targeted therapy.Source filing
ATR-12 — Topline data
H2 2026
• Topline data from the Phase 1b trial is anticipated H2 2026.Source filing
ATR-COSF — Initial data
H2 2026
We plan to conduct a cosmetic study to evaluate the effect of the ingredient on human participants in the second half of 2026.Source filing
ATR-04 — Topline data
Q4-2026
Topline data from first cohort of Phase 1/2 trial expected in Q4-2026.Source filing